**STRN-ALK Fusion–Positive Case of Breast Cancer With Response to Alectinib**

Andrew D. Kelly, MD, PhD; Tom Wiklund, MD, PhD; Juha Kononen, MD, PhD; and James Creeden, MD, PhD

### Introduction

Anaplastic lymphoma kinase (ALK) fusion rearrangements were first described in anaplastic large cell lymphoma and subsequently defined in non–small-cell lung cancer (NSCLC) as capable of inducing malignant transformation.\(^1\) Such fusion events in cancer involve numerous partner genes, but invariably retain the ALK kinase domain coded for by exon 20 and are present in about seven percent of NSCLC cases.\(^3\) Recent data have demonstrated high overall response rates and improved progression-free survival with ALK-directed kinase inhibitors including entrectinib, alectinib, and brigatinib in NSCLC, but have limited data in other tumor types.\(^5-9\) One recent study of 4,854 genomically sequenced breast cancer (BC) cases identified one EML4-ALK fusion in a patient with estrogen receptor–positive disease.\(^10\) Another study using exon arrays identified another five cases with EML4-ALK; however, we are not aware of other published cases involving EML4 or other ALK fusion partners.\(^11\) Here, we report the first case of STRN-ALK fusion–positive BC in a patient who responded to alectinib.

### Case Report

A 52-year-old woman presented with a breast mass. Whole-body computed tomography (CT) did not show evidence of distant metastasis and the patient was treated with mastectomy. Histopathology demonstrated grade 3 papillary adenocarcinoma, which was estrogen receptor–positive, progesterone receptor–negative, and human epidermal growth factor receptor 2–negative. She received adjuvant therapy with docetaxel, cyclophosphamide, epirubicin, and fluorouracil. She also underwent adjuvant radiation and received tamoxifen, with clinical stability for 9 months postsurgery. The patient subsequently presented with widespread advanced BC and received several further lines of systemic treatment. The patient progressed on docetaxel, experienced a partial response to pacitaxel and carboplatin, and progressed again on palbociclib with letrozole. Her condition continued to deteriorate. A schematic of this clinical history and lines of therapy is diagrammed in Figure 1A. She presented at Docrates Cancer Center in October 2020. A liver lesion was biopsied and sent for comprehensive genomic profiling using the FoundationOneCDx panel interrogating 324 genes involved in cancer (Foundation Medicine, Cambridge, MA).\(^12\) The primary mastectomy specimen was also sent to Foundation Medicine for genomic profiling, and patient consent was obtained for publication of genomic and clinical data. The primary tumor and liver metastasis were both found to be GATA-binding protein 3–positive and thyroid transcription factor 1–negative.

The NGS results demonstrated an STRN-ALK fusion rearrangement (S3; A20, Fig 1B), a TP53 R306* nonsense mutation, and an MSH6 duplication involving exons 4-9 in both the primary and metastatic tissue samples. Despite a potentially inactivating MSH6 alteration, both samples demonstrated a tumor mutation burden of three mutations per megabase and microsatellite stability (which was orthogonally confirmed by immunohistochemistry for mismatch repair proteins). Several low-level copy-number amplifications were also identified in the liver metastasis only (Table 1). The sequenced breast primary sample demonstrated relatively high tumor content (60% \(v\) 31% in liver metastasis), suggesting these copy-number alterations were likely acquired during tumor progression (rather than present but not detected in the breast primary). Based on the presence of the STRN-ALK fusion, the patient was started on alectinib with a baseline CT shown at day 7 of treatment (Fig 1C), and a baseline cell-free tumor DNA (cfDNA) measurement of 45.6 ng/mL. During follow-up on day 19 on alectinib, cfDNA was noted to be 5.82 ng/mL and whole-body CT imaging demonstrated partial response (Fig 1C). After progression on day 31, STRN-ALK was no longer detectable in cfDNA and patient consent was obtained for patient treatment with brigatinib, which was well tolerated.

There appeared to be continued response in bone lesions and lymph nodes, with increased cfDNA to 19.45 ng/mL at the time of this writing, and the patient decided not to pursue additional lines of therapy or testing.

Written consent was obtained from the patient discussed in this manuscript that results from genetic profiling and subsequent and previous clinical data can be published. The consent was reviewed by appropriate outside ethics counsel that represents institutional review board for Docrates as a private hospital.
FIG 1. Clinical course of STRN-ALK-driven breast cancer: (A) timeline of therapies and patient response, (B) diagram of STRN-ALK fusion rearrangement, and (C) baseline and follow-up CT scans after initiating alectinib therapy. CT, computed tomography; LHRH, luteinizing hormone-releasing hormone; NGS, next generation sequencing.
TABLE 1. Genomic Alterations Detected by NGS

| PRIMARY TUMOR (ESTIMATED TUMOR PURITY = 60%) | METASTASIS (ESTIMATED TUMOR PURITY = 31%) |
|--------------------------------------------|------------------------------------------|
| Tumor mutation burden = 3 mutations/megabase | Tumor mutation burden = 3 mutations/megabase |
| Microsatellite stable                       | Microsatellite stable                     |
| STRN-ALK fusion                             | STRN-ALK fusion                           |
| TP53 R306* (variant allele frequency = 47.6%) | TP53 R306* (variant allele frequency = 31.7%) |
| MSH6 duplication exons 4-9                  | MSH6 duplication exons 4-9                |
| CCND2 amplification                         |                                         |
| BRAF amplification                          |                                         |
| FGF23 amplification                         |                                         |
| FGF6 amplification                          |                                         |
| KDM5A amplification                         |                                         |
| KEL amplification                           |                                         |
| LYN amplification—equivocal                 |                                         |

Discussion

Alectinib is a selective tyrosine kinase inhibitor approved by the US Food and Drug Administration for ALK-positive NSCLC based on extensive clinical data showing high overall response rates and improved outcomes compared with crizotinib. ALK fusion rearrangements in other tumor types are rare, and there are limited data supporting the role of ALK-directed agents in BC. The case report described here helps address at least two open questions. First, the most common ALK fusion partner described in solid tumors is EML4, and there are multiple distinct rearrangement breakpoints reported with different associations with clinical outcomes. The rarity of STRN as a fusion partner has precluded large analyses to date evaluating sensitivity of STRN-ALK–positive solid tumors to ALK inhibitors with only a handful of published case reports. Several patients with lung adenocarcinoma positive for STRN-ALK were shown to respond to ALK-directed agents. Another patient with malignant mesothelioma achieved a response to ceritinib. This patient's response to alectinib suggests that the STRN-ALK (S3; A20) fusion is likely ALK inhibitor–sensitive. Second, ALK fusions are exceedingly rare in breast tumors, and this case identifies a novel initial driver event as demonstrated by the presence of STRN-ALK in both primary mastectomy and liver metastatic specimens. The existing published case of EML4-ALK–positive BC identified the fusion only in a posthormonal therapy progression sample, suggesting a mechanism of resistance, but not necessarily a tumor-initiating event. The presence of STRN-ALK in this patient's mastectomy sample—and the relative paucity of other alterations—suggests that in this case, the STRN-ALK fusion may have been the transforming event. Interestingly, this observation is in line with multiple analyses of colorectal carcinomas harboring kinase gene fusions, which demonstrate a relative lack of pathogenic alterations in other oncogenic drivers like BRAF or KRAS, and enrichment for microsatellite instability because of MLH1 promoter methylation. Although this patient had microsatellite stable disease, they also harbored an MSH6 alteration affecting a similar region to a reported germline variant, potentially representing a shared molecular phenotype.

The pattern of progression this patient experienced after two months on targeted therapy after response hints that genomic heterogeneity of metastatic sites could drive alectinib resistance, as multiple alterations were present in the liver but absent in the primary tumor. Because of the comparable sample quality and tumor content, it is unlikely that these differences were technical in nature. Of note, there were no identified ALK substitution mutations reported to cause kinase inhibitor resistance, but the amplification of wild-type BRAF represents at least a theoretical mechanism for bypass oncogenic signaling independent of ALK activity. To our knowledge, amplification of wild-type BRAF has not been reported as a mechanism of resistance to alectinib, but merits further study. Because of patient preferences, additional sequencing at the time of progression on alectinib was not pursued; so, we are unable to determine whether any established mechanisms of acquired resistance were present. However, in the setting of lung adenocarcinoma, alectinib resistance has been reported in one STRN-ALK–positive patient who lacked known resistance mutations, suggesting alternative mechanisms may be responsible. In summary, to our knowledge, we present the first case of STRN-ALK fusion–driven BC with response to alectinib. This case highlights clinical actionability derived from comprehensive genomic profiling results outside standard-of-care BC management, which would not otherwise interrogate ALK. Patients with advanced BC harboring rare fusion rearrangements may benefit from therapies shown to benefit other more common fusion partners in other tumor types.

AFFILIATIONS

1 Foundation Medicine Inc, Cambridge, MA
2 Docrates Cancer Center, Helsinki, Finland

CORRESPONDING AUTHOR

Andrew D. Kelly, MD, PhD, Foundation Medicine Inc, 150 Second St, Cambridge, MA 02141; e-mail: akelly@foundationmedicine.com.

AUTHOR CONTRIBUTIONS

Conception and design: All authors
Administrative support: James Creeden
Collection and assembly of data: All authors
Data analysis and interpretation: All authors
Manuscript writing: All authors
Final approval of manuscript: All authors
Accountable for all aspects of the work: All authors
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST
The following represents disclosure information provided by the authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/po/author-center.
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Andrew D. Kelly
Employment: Foundation Medicine
Stock and Other Ownership Interests: Foundation Medicine, Roche
Consulting or Advisory Role: Genospace
Research Funding: Foundation Medicine

REFERENCES
1. Morris SW, Kirstein MN, Valentine MB, et al: Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science 263:1281-1284, 1994
2. Soda M, Choi YL, Enomoto M, et al: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448:561-566, 2007
3. Hallberg B, Palmer RH: The role of the ALK receptor in cancer biology. Ann Oncol 27:iii4-iii15, 2016 (suppl 3)
4. Jordan EJ, Kim HR, Arcila ME, et al: Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies. Cancer Discov 7:596-609, 2017
5. Gao Q, Liang WW, Foltz SM, et al: Driver fusions and their implications in the development and treatment of human cancers. Cell Rep 23:227-238.e3, 2018
6. Camidge DR, Dziadziuszko R, Peters S, et al: Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib in untreated ALK-positive advanced non-small cell lung cancer in the global phase III ALEX study. J Thorac Oncol 14:1233-1243, 2019
7. Hida T, Nokihara H, Kondo M, et al: Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): An open-label, randomised phase 3 trial. Lancet 390:29-39, 2017
8. Camidge DR, Kim HR, Ahn MJ, et al: Brigatinib versus crizotinib in advanced ALK inhibitor-naive ALK-positive non-small cell lung cancer: Second interim analysis of the phase III ALTA-1L trial. J Clin Oncol 38:3592-3603, 2020
9. Drilon A, Siena S, Ou SI, et al: Safety and antitumor activity of the multtargeted Pan-TRK, ROS1, and ALK inhibitor entrectinib: Combined results from two phase I trials (ALKA-372-001 and STARTRK-1). Cancer Discov 7:400-409, 2017
10. Ross DS, Liu B, Schram AM, et al: Enrichment of kinase fusions in ESR1 wild-type, metastatic breast cancer revealed by a systematic analysis of 4854 patients. Ann Oncol 31:991-1000, 2020
11. Lin E, Li L, Guan Y, et al: Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancer. Mol Cancer Res 7:1466-1476, 2009
12. Frampton GM, Fichtenholtz A, Otto GA, et al: Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 31:1023-1031, 2013
13. Lin JJ, Zhu WV, Yoda S, et al: Impact of EML4-ALK variant on resistance mechanisms and clinical outcomes in ALK-positive lung cancer. J Clin Oncol 36:1199-1206, 2018
14. Zhou C, Zeng L, Zhang Y, et al: Responder of gefitinib plus crizotinib in osimertinib failure EGFR-mutant NSCLC-resistant with newly identified STRN-ALK by next-generation sequencing. J Thorac Oncol 14:e143-e144, 2019
15. Yang Q, Qin SK, Zhu J, et al: A rare STRN-ALK fusion in lung adenocarcinoma identified using next-generation sequencing-based circulating tumor DNA profiling exhibits excellent response to crizotinib. Mayo Clin Proc Innov Qual Outcomes 1:111-116, 2017
16. Nagasaka M, Sanavedabatla N, Iwata S, et al: STRN-ALK, a novel in-frame fusion with response to alectinib. JTO Clin Res Rep 2:100125, 2021
17. Ruschoff JH, Gradhand E, Kahraman A, et al: STRN-ALK rearranged malignant peritoneal mesothelioma with dramatic response following ceritinib treatment. Cancer Discov 6:1118-1133, 2016
18. Gainor JF, Dardaei L, Yoda S, et al: Molecular mechanisms of resistance to ceritinib plus crizotinib in osimertinib failure EGFR-mutant NSCLC-resistant with newly identified STRN-ALK by next-generation sequencing. J Thorac Oncol 12:e202-e204, 2017